317 related articles for article (PubMed ID: 28899973)
21. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
[TBL] [Abstract][Full Text] [Related]
22. The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status.
Karnes RJ; Cheville JC; Ida CM; Sebo TJ; Nair AA; Tang H; Munz JM; Kosari F; Vasmatzis G
Cancer Res; 2010 Nov; 70(22):8994-9002. PubMed ID: 21062978
[TBL] [Abstract][Full Text] [Related]
23. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
Lobo J; Rodrigues Â; Antunes L; Graça I; Ramalho-Carvalho J; Vieira FQ; Martins AT; Oliveira J; Jerónimo C; Henrique R
Urol Oncol; 2018 Apr; 36(4):161.e7-161.e17. PubMed ID: 29174711
[TBL] [Abstract][Full Text] [Related]
24. Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.
Neubauer E; Wirtz RM; Kaemmerer D; Athelogou M; Schmidt L; Sänger J; Lupp A
Oncotarget; 2016 Jul; 7(27):41959-41973. PubMed ID: 27259241
[TBL] [Abstract][Full Text] [Related]
25. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms.
Zeng S; Liu A; Dai L; Yu X; Zhang Z; Xiong Q; Yang J; Liu F; Xu J; Xue Y; Sun Y; Xu C
BMC Cancer; 2019 Jun; 19(1):604. PubMed ID: 31216997
[TBL] [Abstract][Full Text] [Related]
27. DNA topoisomerase II alpha promotes the metastatic characteristics of glioma cells by transcriptionally activating β-catenin.
Liu Y; Ma J; Song JS; Zhou HY; Li JH; Luo C; Geng X; Zhao HX
Bioengineered; 2022 Feb; 13(2):2207-2216. PubMed ID: 35012441
[TBL] [Abstract][Full Text] [Related]
28. Identification of enhancer of zeste homolog 2 expression in peripheral circulating tumor cells in metastatic prostate cancer patients: a preliminary study.
Cho KS; Oh HY; Lee EJ; Hong SJ
Yonsei Med J; 2007 Dec; 48(6):1009-14. PubMed ID: 18159594
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical validation of overexpressed genes identified by global expression microarrays in adrenocortical carcinoma reveals potential predictive and prognostic biomarkers.
Ip JC; Pang TC; Glover AR; Soon P; Zhao JT; Clarke S; Robinson BG; Gill AJ; Sidhu SB
Oncologist; 2015 Mar; 20(3):247-56. PubMed ID: 25657202
[TBL] [Abstract][Full Text] [Related]
30. Interaction network analysis of YBX1 for identification of therapeutic targets in adenocarcinomas.
Murugesan SN; Yadav BS; Maurya PK; Chaudhary A; Singh S; Mani A
J Biosci; 2019 Jun; 44(2):. PubMed ID: 31180040
[TBL] [Abstract][Full Text] [Related]
31. The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer.
Zhao SG; Evans JR; Kothari V; Sun G; Larm A; Mondine V; Schaeffer EM; Ross AE; Klein EA; Den RB; Dicker AP; Karnes RJ; Erho N; Nguyen PL; Davicioni E; Feng FY
Clin Cancer Res; 2016 Apr; 22(7):1777-86. PubMed ID: 26631616
[TBL] [Abstract][Full Text] [Related]
32. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
Mo F; Lin D; Takhar M; Ramnarine VR; Dong X; Bell RH; Volik SV; Wang K; Xue H; Wang Y; Haegert A; Anderson S; Brahmbhatt S; Erho N; Wang X; Gout PW; Morris J; Karnes RJ; Den RB; Klein EA; Schaeffer EM; Ross A; Ren S; Sahinalp SC; Li Y; Xu X; Wang J; Wang J; Gleave ME; Davicioni E; Sun Y; Wang Y; Collins CC
Eur Urol; 2018 Apr; 73(4):524-532. PubMed ID: 28330676
[TBL] [Abstract][Full Text] [Related]
33. The polycomb group protein EZH2 is involved in progression of prostate cancer.
Varambally S; Dhanasekaran SM; Zhou M; Barrette TR; Kumar-Sinha C; Sanda MG; Ghosh D; Pienta KJ; Sewalt RG; Otte AP; Rubin MA; Chinnaiyan AM
Nature; 2002 Oct; 419(6907):624-9. PubMed ID: 12374981
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines.
Karanikolas BD; Figueiredo ML; Wu L
Prostate; 2010 May; 70(6):675-88. PubMed ID: 20087897
[TBL] [Abstract][Full Text] [Related]
35. Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer.
Zhao S; Geybels MS; Leonardson A; Rubicz R; Kolb S; Yan Q; Klotzle B; Bibikova M; Hurtado-Coll A; Troyer D; Lance R; Lin DW; Wright JL; Ostrander EA; Fan JB; Feng Z; Stanford JL
Clin Cancer Res; 2017 Jan; 23(1):311-319. PubMed ID: 27358489
[TBL] [Abstract][Full Text] [Related]
36. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
[TBL] [Abstract][Full Text] [Related]
37. TOP2A and CENPF are synergistic master regulators activated in cervical cancer.
Yu B; Chen L; Zhang W; Li Y; Zhang Y; Gao Y; Teng X; Zou L; Wang Q; Jia H; Liu X; Zheng H; Hou P; Yu H; Sun Y; Zhang Z; Zhang P; Zhang L
BMC Med Genomics; 2020 Oct; 13(1):145. PubMed ID: 33023625
[TBL] [Abstract][Full Text] [Related]
38. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
39. TOP2A, HELLS, ATAD2, and TET3 Are Novel Prognostic Markers in Renal Cell Carcinoma.
Chen D; Maruschke M; Hakenberg O; Zimmermann W; Stief CG; Buchner A
Urology; 2017 Apr; 102():265.e1-265.e7. PubMed ID: 28069330
[TBL] [Abstract][Full Text] [Related]
40. MiR-599 targeting TOP2A inhibits the malignancy of bladder cancer cells.
Zhang F; Wu H
Biochem Biophys Res Commun; 2021 Sep; 570():154-161. PubMed ID: 34284141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
